Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Zollner-Schwetz, I; König, E.
Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
Curr Opin Urol. 2023; 33(3):173-179
Doi: 10.1097/MOU.0000000000001084
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Zollner-Schwetz Ines
- Co-authors Med Uni Graz
- König Elisabeth
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE OF REVIEW: Infections due to multidrug-resistant (MDR) Gram-negative bacteria are challenging to treat because of limited treatment options and potential side effects of less frequently used anti-infectives. In the past few years, several new antimicrobial agents effective against MDR Gram-negatives have become available. This review focuses on the treatment options for complicated urinary tract infections (cUTIs) caused by MDR Gram-negatives. RECENT FINDINGS: The novel combinations, betalactam or carbapenem and betalactamase inhibitor, ceftazidime/avibactam and meropenem/vaborbactam, are effective for infections caused by KPC-carbapenemase-producing pathogens. Imipenem/relebactam, another carbapenem/betalactamase inhibitor combination, has been approved for the treatment of cUTI. However, data on the efficacy of imipenem/relebactam against carbapenem-resistant pathogens is still limited. Ceftolozane/tazobactam is mainly used for the treatment of MDR Pseudomonas aeruginosa infections. For the treatment of cUTI caused by extended-spectrum betalactamases producing Enterobacterales aminoglycosides or intravenous fosfomycin should be considered. SUMMARY: To ensure prudent use and to avoid the development of resistance to novel anti-infective substances, an interdisciplinary approach, including urologists, microbiologists, and infectious disease physicians, is strongly advised.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Gram-Negative Bacterial Infections - drug therapy, chemically induced
- Anti-Bacterial Agents - adverse effects
- Urinary Tract Infections - drug therapy
- beta-Lactamase Inhibitors - pharmacology, therapeutic use
- Carbapenems - pharmacology, therapeutic use
- Imipenem - therapeutic use
- Find related publications in this database (Keywords)
- carbapenem-resistant Acinetobacter baumannii
- carbapenem-resistant Enterobacterales
- carbapenem-resistant Pseudomonas aeruginosa
- complicated urinary tract infections